Nuvation Bio (NUVB) presented a detailed update at the second day of the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 10, 2026. The company emphasized the performance of its ROS1 inhibitor, IBTROZI, and the IDH1 inhibitor, safusidenib, while underscoring a robust balance sheet.
The firm reported $700 million in cash and a market capitalization of $2.18 billion. Gross profit margin stands at 88%, and revenue has risen more than 1,000 % over the prior twelve months, according to the Q2 2026 figures. The stock closed at $6.28 on October 9, down 3.68%, but rose to $6.349 in after‑hours trading, a 1.10% gain. Analyst price targets range from $7 to $21, reflecting a 96 % total return over the past year and a 39 % increase in the last six months.
IBTROZI, launched just over a year ago, captured roughly 20 % of its addressable market in the first year. Patient starts have risen from 70 in Q1 to 140 in Q4, with current enrollment averaging 50 patients per month against a theoretical 250‑patient monthly market. First‑line usage now accounts for about 85 % of starts, up from 30‑40 % at launch. Clinical data show a 90 % response rate in the first‑line setting and a 15‑month median duration of response, with an intracranial response of 66 % versus 48 % for the competing JUDGE‑RETRO trial. The company projects peak annual sales of $4‑$5 billion at full market penetration, with a revenue‑stacking model of $1 billion in year 1, $2 billion in year 2, $3 billion in year 3 and $4 billion in year 4, driven by an anticipated 50‑month response duration.
Safusidenib, the IDH1 inhibitor for gliomas, reported 3‑year follow‑up data showing a 79 % non‑progression rate and a 52 % response rate, up from 44 % earlier. The company highlighted a case of glioblastoma with tumor disappearance lasting 3.5 years, suggesting potential immune‑oncology activity. Nuvation plans a grade 3 oligodendroglioma trial in 2027 enrolling 40 patients, with additional readouts from the SIGMA progression‑free survival study and an INDIGO‑type placebo‑controlled trial slated for 2029. A platform update for its two‑small‑molecule drug‑conjugate (DDC) system is expected in the second half of the year.
CEO David described IBTROZI as “the best ROS1 drug” based on efficacy and durability, while CFO Philip noted the $700 million cash position provides ample runway to profitability. The executives also referenced the AnHeart deal as a model for future acquisitions that could bridge the gap to the anticipated 2029 safusidenib approval.
Overall, Nuvation Bio’s conference briefing combined strong clinical readouts with ambitious commercial forecasts and a solid financial foundation, positioning the company for continued growth in the oncology market.
